Protocol for the Examination of Specimens From Patients With Carcinomas of the Salivary Glands

Protocol applies to all invasive carcinomas of the parotid, submandibular, and sublingual glands. Melanomas, lymphomas, and sarcomas are not included. Minor salivary gland carcinomas are detailed in upper aerodigestive tract site-specific protocols.

Based on AJCC/UICC TNM, 7th edition
Protocol web posting date: October 2013

Procedure
• Biopsy
• Resection

Authors
Diane L. Carlson, MD, FCAP*
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
Ilan Weinreb, MD, FCAP
Department of Anatomical Pathology, University Health Network, Toronto, ON
Jonathan B. McHugh, MD, FCAP
Department of Pathology, University of Michigan, Ann Arbor, MI
Louis B. Harrison, MD
Department of Radiation Oncology, Beth Israel Medical Center, St. Luke’s and Roosevelt Hospitals, New York, NY
Mary S. Richardson, MD, DDS
Department of Pathology, Medical University of South Carolina, Charleston, SC
Jatin Shah, MD, FACS
Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
Robert L Ferris, MD, PhD, FACS
Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Bruce M. Wenig, MD, FCAP
Department of Pathology and Laboratory Medicine, Beth Israel Medical Center, St. Luke’s and Roosevelt Hospitals, New York, NY
Lester D. R. Thompson, MD, FCAP
Department of Pathology, Southern California Permanente Medical Group, Woodland Hills, CA
Raja R. Seethala, MD, FCAP†
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
For the Members of the Cancer Committee, College of American Pathologists

* Denotes primary author. † Denotes senior author. All other contributing authors are listed alphabetically.

Previous contributors: Ben Z. Pilch, MD; Elizabeth Gillies, MD; John R. Houck Jr, MD; Kyung-Whan Min, MD; David Novis, MD; Jatin Shah, MD; Richard J. Zarbo, MD, DMD; Bruce M Wenig, MD
The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) Dictation from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) Copying from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a computerized system for items (1) and (2), provided that the protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from the CAP.

Any public dissemination of the original or modified protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.
CAP Salivary Gland Protocol Revision History

Version Code
The definition of the version code can be found at www.cap.org/cancerprotocols.

Version: SalivaryGland 3.2.0.0

Summary of Changes
The following changes have been made since the June 2012 release.

Incisional Biopsy, Excisional Biopsy, Resection

Histologic Type
Low, intermediate, and high grade were added to adenoid cystic carcinoma as follows:

___ Adenoid cystic carcinoma
    ___ Low grade
    ___ Intermediate grade
    ___ High grade

"Clear cell adenocarcinoma" was changed to "(Hyalinizing) clear cell carcinoma"; "Mammary analogue secretory carcinoma" was added; "Large cell carcinoma" and "Small cell carcinoma" were replaced with "High-grade neuroendocrine carcinoma" with the subtypes of "Large cell neuroendocrine carcinoma" and "Small cell neuroendocrine carcinoma"; and "Cribriform adenocarcinoma of minor salivary origin" was added as a subtype of "Polymorphous low-grade adenocarcinoma."

Margins
Designation of distance of tumor from closest margin was changed from “mm or cm” to millimeters (mm).

Pathologic Staging (pTNM)
Regional Lymph Nodes (pN)
Number of Lymph Nodes Involved
Size (greatest dimension) of the largest “positive lymph node” was changed to largest “metastatic focus in the lymph node.”

Explanatory Notes

Scope of Guidelines: First sentence: “oral cancer including the lip” was changed to “major salivary gland cancer.”

B. Histologic Type
Histologic types were updated.

C. Histologic Grade; D. Surgical Margins; F. Perineural Invasion; G. Extranodal Extension; J. Classification of Neck Dissection; L. Lymph Nodes; M. Ancillary Testing
Edits were made to these notes.

K. Regional Lymph Nodes (pN0): Isolated Tumor Cells: Classification scheme for ITCs was deleted.

References: References were updated.
Surgical Pathology Cancer Case Summary

Protocol web posting date: October 2013

MAJOR SALIVARY GLANDS: Incisional Biopsy, Excisional Biopsy, Resection

Select a single response unless otherwise indicated.

Specimen (select all that apply) (Note A)
___ Parotid gland
   ___ Superficial lobe only
   ___ Deep lobe only
   ___ Total parotid gland
___ Submandibular gland
___ Sublingual gland
___ Other (specify): _________________________
___ Not specified

Received:
___ Fresh
___ In formalin
___ Other (specify): _________________________

Procedure (select all that apply)
___ Incisional biopsy
___ Excisional biopsy
___ Resection, parotid gland
   ___ Superficial parotidectomy
   ___ Total parotidectomy
___ Resection, submandibular gland
___ Resection, sublingual gland
___ Neck (lymph node) dissection (specify): __________________________
___ Other (specify): __________________________
___ Not specified

+ Specimen Integrity
  + ___ Intact
  + ___ Fragmented

Specimen Size
Greatest dimensions: ____ x ____ x ____ cm
+ Additional dimensions (if more than 1 part): ____ x ____ x ____ cm

Specimen Laterality
___ Right
___ Left
___ Bilateral
___ Not specified

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
**Tumor Site (select all that apply) (Note A)**

- ___ Parotid gland
  - ___ Superficial lobe
  - ___ Deep lobe
  - ___ Entire parotid gland
- ___ Submandibular gland
- ___ Sublingual gland
- ___ Other (specify): ____________________________
- ___ Not specified

**Tumor Focality**

- ___ Single focus
- ___ Bilateral
- ___ Multifocal (specify): ____________________________

**Tumor Size**

Greatest dimension: ___ cm

+ Additional dimensions: ___ x ___ cm

___ Cannot be determined (see Comment)

**+ Tumor Description (select all that apply)**

+ ___ Encapsulated/circumscribed
+ ___ Invasive
+ ___ Solid
+ ___ Cystic
+ ___ Other (specify): ____________________________

**+ Macroscopic Extent of Tumor (extent of invasion)**

+ Specify: ____________________________

**Histologic Type (select all that apply) (Note B)**

- ___ Acinic cell carcinoma
- ___ Adenoid cystic carcinoma
  - ___ Low grade
  - ___ Intermediate grade
  - ___ High grade
- ___ Adenocarcinoma, not otherwise specified (NOS)
  - ___ Low grade
  - ___ Intermediate grade
  - ___ High grade
- ___ Basal cell adenocarcinoma
- ___ Carcinoma ex pleomorphic adenoma (malignant mixed tumor)
  - ___ Low grade
  - ___ High grade
  - ___ Invasive
    - ___ Minimally invasive (Note C)
    - ___ Invasive (Note C)
    - ___ Intracapsular (noninvasive)
- ___ Carcinosarcoma (true malignant mixed tumor)
- ___ (Hyalinizing) clear cell carcinoma
- ___ Cystadenocarcinoma
- ___ Epithelial-myoeipithelial carcinoma

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
___ Low-grade cribriform cystadenocarcinoma
___ Lymphoepithelial carcinoma
___ Mammary analogue secretory carcinoma
___ Metastasizing pleomorphic adenoma
___ Mucoepidermoid carcinoma
   ___ Low grade
   ___ Intermediate grade
   ___ High grade
___ Mucinous adenocarcinoma (colloid carcinoma)
___ High-grade neuroendocrine carcinoma
   ___ Large cell neuroendocrine carcinoma
   ___ Small cell neuroendocrine carcinoma
___ Myoepithelial carcinoma (malignant myoepithelioma)
___ Oncocytic carcinoma
___ Polymorphous low-grade adenocarcinoma
   ___ Cribriform adenocarcinoma of minor salivary origin
___ Salivary duct carcinoma
___ Sebaceous adenocarcinoma
___ Sebaceous lymphadenocarcinoma
___ Sialoblastoma
___ Squamous cell carcinoma, primary
___ Undifferentiated carcinoma, large cell type
___ Other (specify): ____________________________
___ Carcinoma, type cannot be determined

Histologic Grade (Note C)
___ Not applicable
___ GX: Cannot be assessed
___ G1: Well differentiated
___ G2: Moderately differentiated
___ G3: Poorly differentiated
___ Other (specify): ____________________________

+ Microscopic Tumor Extension
+ Specify: ____________________________

Margins (Notes D and E)
___ Cannot be assessed
___ Margins uninvolved by carcinoma
   Distance of tumor from closest margin: ___ mm
   Specify margin, if possible: ____________________________
___ Margin(s) involved by carcinoma
   Specify margin(s), if possible: ____________________________

+ Treatment Effect (applicable to carcinomas treated with neoadjuvant therapy)
+ ___ Not identified
+ ___ Present (specify): ____________________________
+ ___ Indeterminate

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
Lymph-Vascular Invasion
___ Not identified
___ Present
___ Indeterminate

Perineural Invasion (Note F)
___ Not identified
___ Present
___ Indeterminate

Lymph Nodes, Extranodal Extension (Note G)
___ Not identified
___ Present
___ Indeterminate

Pathologic Staging (pTNM) (Note H)

Note: The phrases in italics include clinical findings required for AJCC staging. This clinical information may not be available to the pathologist. However, if known, these findings should be incorporated into the pathologic staging.

TNM Descriptors (required only if applicable) (select all that apply)
___ m (multiple primary tumors)
___ r (recurrent)
___ y (posttreatment)

Primary Tumor (pT)
___ pTX: Cannot be assessed
___ pT0: No evidence of primary tumor
___ pT1: Tumor 2 cm or less in greatest dimension without extraparenchymal extension (Note I)
___ pT2: Tumor more than 2 cm but not more than 4 cm in greatest dimension without extraparenchymal extension (Note I)
___ pT3: Tumor more than 4 cm and/or tumor having extraparenchymal extension (Note I)
___ pT4a: Moderately advanced disease. Tumor invades skin, mandible, ear canal, and/or facial nerve.
___ pT4b: Very advanced local disease. Tumor invades skull base and/or pterygoid plates and/or encases carotid artery

Note: There is no category of carcinoma in situ (pTis) relative to carcinomas of salivary glands (major, minor).

Regional Lymph Nodes (pN)* (Notes J through M)
___ pNX: Cannot be assessed
___ pN0: No regional lymph node metastasis
___ pN1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
___ pN2a: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
___ pN2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
___ pN2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
___ pN3: Metastasis in a lymph node, more than 6 cm in greatest dimension
___ No nodes submitted or found

* Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
Number of Lymph Nodes Examined
Specify: ___
___ Number cannot be determined (explain): ______________________

Number of Lymph Nodes Involved
Specify: ___
+ Size (greatest dimension) of the largest metastatic focus in the lymph node: ___ cm (Note L)
___ Number cannot be determined (explain): ______________________
# Superior mediastinal lymph nodes are considered regional lymph nodes (level VII). Midline nodes are considered ipsilateral nodes.

Distant Metastasis (pM)
___ Not Applicable
___ pM1: Distant metastasis
   + Specify site(s), if known: ______________________

+ Additional Pathologic Findings (select all that apply)
+ ___ Sialadenitis
+ ___ Tumor associated lymphoid proliferation (TALP)
+ ___ Other (specify): ______________________

+ Ancillary Studies (Note N)
+ Specify type(s): ______________________
+ Specify result(s): ______________________

+ Clinical History (select all that apply)
+ ___ Neoadjuvant therapy
   + ___ Yes (specify type): ______________________
   + ___ No
   + ___ Indeterminate
+ ___ Other (specify): ______________________

+ Comment(s)
Explanatory Notes

Scope of Guidelines
The reporting of major salivary gland cancer is facilitated by the provision of a case summary illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a case summary may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the levels of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Case summaries have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. Adjuvant and neoadjuvant therapy can significantly alter histologic findings, making accurate classification an increasingly complex and demanding task. This protocol tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) cancer staging manual, the World Health Organization classification of tumours, the TNM classification, the American College of Surgeons Commission on Cancer, and the International Union on Cancer (UICC). This protocol is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the oral cavity in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.

A. Primary Site (Figure 1)
The classification applies only to carcinomas of the major salivary glands: parotid, submandibular (submaxillary), and sublingual glands. Tumors arising in minor salivary glands (mucous-secreting glands in the lining membrane of the upper aerodigestive tract) are staged according to the classification schemes corresponding to the anatomic sites in which they reside, eg, oral cavity, pharynx, sinonasal tract.

B. Histological Type
The histologic classification recommended is a modification of the World Health Organization (WHO) classification of salivary gland tumors. The listing is in alphabetical order and includes the following:

- Acinic cell carcinoma
- Adenoid cystic carcinoma
- Adenocarcinoma, not otherwise specified (NOS)
  - Low grade
  - Intermediate grade
  - High grade
- Basal cell adenocarcinoma
- Carcinoma ex pleomorphic adenoma (malignant mixed tumor)
  - Low grade
  - High grade
  - Invasive
    - Minimally invasive
    - Invasive
  - Intracapsular (noninvasive)
- Carcinosarcoma (true malignant mixed tumor)
  - (Hyalinizing) clear cell carcinoma
- Cystadenocarcinoma
- Epithelial-myoepithelial carcinoma
- Low-grade cribriform cystadenocarcinoma
- Lymphoepithelial carcinoma
- Mammary analogue secretory carcinoma
- Metastasizing pleomorphic adenoma
- Mucoepidermoid carcinoma
  - Low grade
  - Intermediate grade
  - High grade
- Mucinous adenocarcinoma (colloid carcinoma)
- High-grade neuroendocrine carcinoma
  - Large cell neuroendocrine carcinoma
  - Small cell neuroendocrine carcinoma
- Myoepithelial carcinoma (malignant myoepithelioma)
- Oncocytic carcinoma
- Polymorphous low-grade adenocarcinoma
  - Cribriform adenocarcinoma of minor salivary origin
- Salivary duct carcinoma
- Sebaceous adenocarcinomas
  - Sebaceous adenocarcinoma
  - Sebaceous lymphadenocarcinoma
- Sialoblastoma
- Squamous cell carcinoma, primary
- Undifferentiated carcinoma, large cell type

* These entities were characterized as distinct tumor types subsequent to the WHO classification scheme.
**Metastatic foci are histologically benign. Although not strictly considered a malignant neoplasm, this neoplasm is classified with other salivary gland carcinomas, given the fact that 40% of patients are reported to die of disease even though 60% are alive and well (47%) or are alive with disease (13%).**

**C. Histologic Grade**

The histologic (microscopic) grading of salivary gland carcinomas has been shown to be an independent predictor of behavior and plays a role in optimizing therapy. Further, there is often a positive correlation between histologic grade and clinical stage. Most salivary carcinomas have a biologic behavior defined by their categorization and do not require grading. The 3 major categories that are amenable to grading include adenoid cystic carcinoma, mucoepidermoid carcinoma (the 2 most frequent histologic types seen in larynx), and adenocarcinoma, not otherwise specified.

Generally, 3 histologic grades are suggested, as follows:

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Well differentiated = Low-grade</td>
</tr>
<tr>
<td>2</td>
<td>Moderately differentiated = Intermediate-grade</td>
</tr>
<tr>
<td>3</td>
<td>Poorly differentiated = High-grade</td>
</tr>
<tr>
<td>X</td>
<td>Cannot be assessed</td>
</tr>
</tbody>
</table>

In some carcinomas, histologic grading may be based on growth pattern, such as in adenoid cystic carcinoma, for which a histologic high-grade variant has been recognized based on the percentage of solid growth. Those adenoid cystic carcinomas showing 30% or greater of solid growth pattern are considered to be histologically high-grade carcinomas. The histologic grading of mucoepidermoid carcinoma includes a combination of growth pattern characteristics (eg, cystic, solid, neurotropism) and cytomorphologic findings (eg, anaplasia, mitoses, necrosis). Adenocarcinomas, not otherwise specified, do not have a formalized grading scheme and are graded intuitively based on cytomorphologic features.

**D. Surgical Margins**

Complete surgical excision to include cancer-free surgical margins is the primary mode of therapy for salivary gland cancers, as retrospective studies have shown an increased risk for recurrence and decreased survival with positive surgical margins. The need for additional surgery is determined on the basis of histopathologic review; positive surgical margins are an indication for additional resection to ensure total tumor removal. Carcinoma in situ of the salivary glands are exceptionally rare and constitute mainly salivary duct carcinoma in situ, low-grade cribriform cystadenocarcinoma (both of which have been referred to as intraductal carcinoma), and possibly a subset of cystadenocarcinomas.

**E. Orientation of Specimen**

Complex specimens should be examined and oriented with the assistance of attending surgeons. Direct communication between the surgeon and pathologist is a critical component in specimen orientation and proper sectioning. Whenever possible, the tissue examination request form should include a drawing of the resected specimen showing the extent of the tumor and its relation to the anatomic structures of the region. The lines and extent of the resection can be depicted on preprinted adhesive labels and attached to the surgical pathology request forms.

**F. Perineural Invasion**

The presence of perineural invasion (neurotropism) is an important predictor of poor prognosis in head and neck cancer of virtually all sites. The majority of studies evaluating the influence of perineural invasion on therapy and prognosis are limited to head and neck squamous cell carcinoma. However, relative to salivary gland carcinomas, facial nerve dysfunction and perineural involvement are factors
Influencing the indication for neck dissection, postoperative radiation therapy, and survival rate. Perineural invasion (neurotropism) in the primary salivary gland carcinomas, especially the facial nerve, is associated with recurrent tumor and decreased survival. Further, facial nerve involvement by carcinoma has been found to be predictive of occult metastases. Among other prognostic indicators, perineural invasion in minor salivary gland tumors has been shown to be statistically significant to the outcome. Given the significance relative to prognosis and treatment, perineural invasion is a required data element in the reporting of salivary gland carcinomas.

G. Extranodal Extension
The status of cervical lymph nodes is the single most important prognostic factor in aerodigestive cancer. All macroscopically negative or equivocal lymph nodes should be submitted in toto. Grossly positive nodes may be partially submitted for microscopic documentation of metastasis. Reporting of lymph nodes containing metastasis should include whether there is presence or absence of extranodal extension (EE). This finding consists of extension of metastatic tumor, present within the confines of the lymph node, through the lymph node capsule into the surrounding connective tissue, with or without associated stromal reaction. A distance of extension from the native lymph node capsule is optional and has not yet been shown to have a definitive impact on prognosis or treatment for head and neck subsites. If macroscopic examination suggests EE, this tissue should be submitted for microscopic confirmation. EE is a predictor of regional relapse and a criterion for postoperative radiotherapy.

H. TNM and Stage Groupings
The protocol recommends the TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) for salivary gland cancer.1,30

Primary Tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor 2 cm or less in greatest dimension without extraparenchymal extension
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension without extraparenchymal extension
T3 Tumor more than 4 cm and/or tumor having extraparenchymal extension
T4a Moderately advanced disease. Tumor invades skin, mandible, ear canal, and/or facial nerve
T4b Very advanced disease. Tumor invades skull base and/or pterygoid plates and/or encases carotid artery

Regional Lymph Nodes *
NX Cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
N3 Metastasis in a lymph node, more than 6 cm in greatest dimension

*Superior mediastinal lymph nodes are considered regional lymph nodes (level VII). Midline nodes are considered ipsilateral nodes.

Distant Metastasis
M0 No distant metastasis
M1 Distant metastasis
By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

Significant changes in the AJCC staging manual include revision of T3 to include all tumors larger than 4cm and division of T4 lesions into T4a and T4b. T4a tumors invade skin, mandible, ear canal, and/or facial nerve. T4b tumors invade skull base and/or pterygoid plates and/or encases carotid artery. T4a are advanced tumors that can be resected with clear margins; T4b are advanced tumors that cannot be resected with clear margins.

### Stage Groupings

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>II</td>
<td>T1, T2, T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>III</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IVA</td>
<td>T4a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4a</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T1, T2, T3, T4a</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>IVB</td>
<td>T4b</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>IVC</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

### TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.
**Additional Descriptors**

**Residual Tumor (R)**
Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>RX</td>
<td>Presence of residual tumor cannot be assessed</td>
</tr>
<tr>
<td>R0</td>
<td>No residual tumor</td>
</tr>
<tr>
<td>R1</td>
<td>Microscopic residual tumor</td>
</tr>
<tr>
<td>R2</td>
<td>Macroscopic residual tumor</td>
</tr>
</tbody>
</table>

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

**I. Extraparenchymal Extension**
Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or nerve (T1, T2, T3), except those listed under T4a and 4b. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.  

**J. Classification of Neck Dissection**
1. Radical neck dissection
2. Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared
3. Selective neck dissection (SND), as specified by the surgeon (Figure 2), defined by dissection of less than the 5 traditional levels of a radical and modified radical neck dissection. The following dissections are now under this category:  
   a. Supraomohyoid neck dissection
   b. Posterolateral neck dissection
   c. Lateral neck dissection
   d. Central compartment neck dissection
4. Superselective neck dissection (SSND), a relatively new term defined by dissection of the fibrofatty elements of 2 or less levels
5. Extended radical neck dissection, as specified by the surgeon

**K. Regional Lymph Nodes (pN0): Isolated Tumor Cells**
Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. While the generic recommendation is that for lymph nodes with ITCs found by either histologic examination, immunohistochemistry, or nonmorphologic techniques (eg, flow cytometry, DNA analysis, polymerase chain reaction [PCR] amplification of a specific tumor marker), they should be classified as N0 or M0, respectively. Evidence for the validity of this practice in head and neck squamous cell carcinoma and other histologic subtypes is lacking. In fact, rare studies relevant to head and neck sites indicate that isolated tumor cells may actually be a poor prognosticator in terms of local control.

For purposes of pathologic evaluation, lymph nodes are organized by levels as shown in Figure 2.
In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and the details of the local anatomy in the specimens they submit for examination or, in other manners, orient those specimens for pathologists.

If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of internal jugular (IJ) vein or neck specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.

**Level I. Submental Group (Sublevel IA)**
Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.

**Level I. Submandibular Group (Sublevel IB)**
Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.

**Level II. Upper Jugular Group (Sublevels IIA and IIB)**
Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.
Level III. Middle Jugular Group
Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiority to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark) inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

Level IV. Lower Jugular Group
Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiority to the clavicle inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

Level V. Posterior Triangle Group (Sublevels VA and VB)
This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.

Level VI. Anterior (Central) Compartment
Lymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries, and the posterior boundary by the prevertebral fascia.

Level VII. Superior Mediastinal Lymph Nodes
Metastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases.

Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. Midline nodes are considered ipsilateral nodes.

L. Lymph Nodes

Lymph Node Number
Histological examination of a selective neck dissection specimen will ordinarily include 6 or more lymph nodes. Histological examination of a radical or modified radical neck dissection specimen will ordinarily include 10 or more lymph nodes in the untreated neck.

Measurement of Tumor Metastasis
The cross-sectional diameter of the largest lymph node metastasis (not the lymph node itself) is measured in the gross specimen at the time of macroscopic examination or, if necessary, on the histologic slide at the time of microscopic examination.²²,³¹

M. Special Procedures for Lymph Nodes
At the current time, no additional special techniques should be used other than routine histology for the assessment of nodal metastases. Immunohistochemistry and PCR to detect isolated tumor cells are considered investigational techniques at this time.

N. Ancillary Testing
At the current time, no additional special techniques are mandatory other than routine histology for the assessment of salivary gland tumors. However the past few years, several salivary gland tumors have
been demonstrated to have unique fusion transcripts that may be considered optional for reporting purposes.

By both reverse transcriptase polymerase chain reaction (RT-PCR) and fluorescence in-situ hybridization (FISH), over 60% of mucoepidermoid carcinoma have been show to demonstrate t(11;19) (q12;p13) translocation.\textsuperscript{15} This aberration leads to a fusion gene comprised of exon 1 of the \textit{CRTC1} (also known as \textit{MECT1}) gene and exons 2-5 of the \textit{MAML2} gene. The resultant \textit{CRTC1}-\textit{MAML2} fusion gene protein appears to activate both Notch signaling targets and cAMP/CREB targets.\textsuperscript{40-42} An alternate fusion partner \textit{CRTC3} has been documented as well.\textsuperscript{43} This translocation is more frequent in low- and intermediate-grade mucoepidermoid carcinomas and is thus considered a more favorable prognosticator, even in the high-grade subgroup.\textsuperscript{11,15}

A more recently described distinct primary salivary gland malignancy, mammary analogue secretory carcinoma, is now known to be defined by the unique translocation t(12;15)(p13;q25), leading to the \textit{ETV6}-\textit{NTRK3} fusion gene.\textsuperscript{4} Historically many of these were grouped with acinic cell carcinoma or adenocarcinoma, not otherwise specified.\textsuperscript{44} Prognosis is roughly similar to that of acinic cell carcinoma, though mammary analogue secretory carcinoma may have a slightly higher risk of nodal metastasis. Similarly, hyalinizing clear cell carcinoma is now known to harbor a defining \textit{EWSR1}-\textit{ATF1} translocation in 80% to 90% of cases.\textsuperscript{45}

Approximately one-third of adenoid cystic carcinomas have been identified with t(6;9)(q22-23;p23-24), resulting in \textit{MYB-NFIB} fusion transcript.\textsuperscript{38,39} The prognostic and therapeutic value for this translocation is not yet established.

Additional ancillary testing that is not uncommonly used for hypothetical therapeutic applications includes immunohistochemical staining for HER2/neu can be identified in association with salivary duct carcinoma. However, at the present time there are no specific recommendations to perform confirmatory FISH analysis similar to mammary duct carcinoma; the utilization of FISH analysis in salivary duct carcinoma or any other salivary gland malignancy is considered an investigational technique at this time. Salivary duct carcinomas frequently express immunoreactivity for hormonal receptors, including androgen receptor and estrogen receptor-beta (usually negative for estrogen receptor-alpha, the more commonly used estrogen immunohistochemical stain).\textsuperscript{46} Although there are no specific recommendations to perform confirmatory immunohistochemistry for hormonal receptors, the expression of androgen receptor and estrogen receptor-beta may potentially guide treatment with targeted multiantigen chemotherapies.\textsuperscript{46} More recently, \textit{PIK3CA} mutations and \textit{PTEN} loss in subsets of salivary duct carcinoma offer additional therapeutic targets, though again on an investigational basis.\textsuperscript{47}

References


